• Save
Researching information needs and beliefs of patients, professionals and the public regarding medicines development - EUPATI - Bella Starling
Upcoming SlideShare
Loading in...5
×
 

Researching information needs and beliefs of patients, professionals and the public regarding medicines development - EUPATI - Bella Starling

on

  • 598 views

"Researching information needs and beliefs of patients, professionals and the public regarding medicines development", presentation held by Bella Starling on 6 March 2013 at DIA EuroMeeting

"Researching information needs and beliefs of patients, professionals and the public regarding medicines development", presentation held by Bella Starling on 6 March 2013 at DIA EuroMeeting

Statistics

Views

Total Views
598
Views on SlideShare
517
Embed Views
81

Actions

Likes
0
Downloads
0
Comments
0

2 Embeds 81

http://www.patientsacademy.eu 80
http://patientsacademy.eu 1

Accessibility

Categories

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

CC Attribution-NonCommercial-ShareAlike LicenseCC Attribution-NonCommercial-ShareAlike LicenseCC Attribution-NonCommercial-ShareAlike License

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

Researching information needs and beliefs of patients, professionals and the public regarding medicines development - EUPATI - Bella Starling Researching information needs and beliefs of patients, professionals and the public regarding medicines development - EUPATI - Bella Starling Presentation Transcript

  • Researching informationneeds and beliefs ofpatients, professionalsand the public regardingmedicines developmentBella Starling PhDWP3 leader, EUPATI 25th AnnualDirector of Public Programmes EuroMeetingNowgen, University of Manchester 4-6 March 2013 RAI, Amsterdam Netherlands
  • Where do we start?• Phase one – Review of existing information resources on medicines development – Literature review exploring patient and public knowledge, understanding and beliefs of medicines development and incentives and barriers to involvement• Phase two – Focus groups with patients and the public, health professionals, policy makers and pharmaceutical industry representatives to explore their perspective on medicines development and patients‟ information needs• Phase three – Survey of patients associated with patient organisations in Europe to explore their information needs and preferences for type of information resource
  • Resource review• A „snapshot‟ of existing resources – Over 300 submissions via EUPATI website – Range of stakeholders submitting material – Categorisation: scientific topic area, audience, format, language, etc – Recommendations for EUPATI content development www.patientsacademy.eu/index.php/en/network/138
  • Resource review - results Medicines Personalis Drug Pharmacoeco Design Patients roles Other developmen ed and safety and nomics, and and t process predictive risk benefit health objective responsibiliti from medicine assessmen economics or s of es research to t of novel health clinical approval or existing technology trials medicines assessment Patient 5 0 3 5 5 6 1advocates Expert 1 1 1 16 1 1 3 patientsPatients at 74 21 77 13 65 42 6 large Total 80 22 81 34 71 49 10
  • Resource review - results Medicines Personalis Drug Pharmacoeco Design Patients roles Other developmen ed and safety and nomics, and and t process predictive risk benefit health objective responsibiliti from medicine assessmen economics or s of es research to t of novel health clinical approval or existing technology trials medicines assessment Patient 5 0 3 5 5 6 1advocates Expert 1 1 1 16 1 1 3 patientsPatients at 74 21 77 13 65 42 6 large Total 80 22 81 34 71 49 10
  • Resource review - results Medicines Personalis Drug Pharmacoeco Design Patients roles Other developmen ed and safety and nomics, and and t process predictive risk benefit health objective responsibiliti from medicine assessmen economics or s of es research to t of novel health clinical approval or existing technology trials medicines assessment Patient 5 0 3 5 5 6 1advocates Expert 1 1 1 16 1 1 3 patientsPatients at 74 21 77 13 65 42 6 large Total 80 22 81 34 71 49 10
  • Recommendations• Medicines development process: adapt existing overviews, tackle specific areas in more detail;• Personalised and predictive medicine: few resources; difficult area for patients to interpret.• Medicines safety and risk-benefit assessment: adapt pharmacovigilance resources aimed at health professionals• HTA: few resources for patients; more needed.• Design & objectives of clinical trials: focus on specific aspects eg. how research priorities are established;• Patient roles & responsibilities: scope for a range of resources• Something to submit? Contact kay.j.warner@gsk.com
  • Literature review• Systematic keyword search across databases, 2002-2012• Knowledge of areas: What do people know/not know? Facilitators/barriers to increasing awareness and understanding.• Attitudes and beliefs & what influences these?• Role of information and training in increasing awareness and involvement: Types of information and training; uptake and impact.• Methods of raising awareness and their impact• Methods of increasing patient and public involvement: what works and what doesn‟t work?• Stages that patients and the public would like to get involved in and why
  • Focus groups/interviews• In England, Spain & Poland: 3xFG Patients, patient advocates 2xFG Members of the public 1xFG Health professionals, policy makers and advisers 1xFG Pharmaceutical professionals• + Pan-European FGs associated with EUPATI events
  • FG preliminary findings Patient advocates beliefs about their roles in relation to research and to medicines development• Multi-faceted role – including involvement in research• Varying degrees of readiness, ability and willingness• Support and training needed for all stakeholders in medicines development “I think that we should try to become more partners (with pharmaceuticalcompanies) … because I think that the reason why we are so sceptic aboutthem, and everything, is because we don’t understand them. And we don’t trust them. And the thing is that, until we actually really can talk to them in their own… or in the same level… then we will feel more confident to actually do things together.”
  • FG preliminary findings Patient advocates – information needs (1)• Information should be: – Accurate and up to date – Quick and easy to navigate – Developed by a credible source – Quality stamp – impartial, trustworthy information – Jargon free “From different sources but with no real links and connections and agendas, interests, conflict of interests. That if EUPATI manages to have this body of experts which could gain or obtain this information they analyse it and then the ideal information which is due to be disseminated and circularised then it’s what attracts the trust that EUPATI would be the source of....”
  • FG preliminary findings Patient advocates – information needs (2)• More information needed: – Science behind / scientific aspects of studies – Benefits and risks of taking part in studies – Empowering and supporting patients • To become involved and engaged in medicines development • To judge whether information is useful – Transparent information about the results of trials – Patient reported outcomes
  • FG preliminary findings Patient advocates – training courses• Expert level courses – Intense, difficult to follow – Prior preparation useful – Guidelines for speakers – Importance of refresher courses – rapidly changing area• Case studies are useful: – From basic research to post marketing – Examples of successful/unsuccessful involvement in research• e-learning + face-to-face• Delivered by patient advocates + academia + experts• 0-4 hours per week• ~6 days/year for face-to-face, block of 2-3 days• Over 1-2 years
  • Next steps• Survey in April 2013• 6 languages of EUPATI; April 2013• Questions: – Current knowledge of medicines development – Information needs about medicines development – Support to increase awarenes & involvement• Targeting: – Patient advocates & expert patients: via POs – Patients & members of the public: through market research organisations• Reaching over 6000 people
  • Workpackage 3 team• University of Manchester• Bella Starling – WP3 lead• Suzanne Parsons – EUPATI Project Manager• Su Gwan Tham – EUPATI Project Assistant• GlaxoSmithKline• Kay Warner – WP3 co-lead• Novo Nordisk• Christine Mullan-Jensen – WP3 Deputy co-lead• EGAN/GAUK• Kim Wever• Celine Lewis• Amgen, Genzyme, Roche, AstraZeneca, VFA
  • DisclaimerThe views and opinions expressed in the following PowerPoint slides arethose of the individual presenter and should not be attributed to DrugInformation Association, Inc. (“DIA”), itsdirectors, officers, employees, volunteers, members, chapters, councils,Special Interest Area Communities or affiliates, or any organization withwhich the presenter is employed or affiliated.These PowerPoint slides are the intellectual property of the individualpresenter and are protected under the copyright laws of the UnitedStates of America and other countries. Used by permission. All rightsreserved. Drug Information Association, DIA and DIA logo are registeredtrademarks or trademarks of Drug Information Association Inc. All othertrademarks are the property of their respective owners. 16